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 35 
ABSTRACT 36 
The effect of 38 µg (1500 IU) daily vitamin D3 supplementation, consumed with an iron-fortified 37 
breakfast cereal for 8 weeks, on haematological indicators in iron-deficient female subjects was 38 
investigated. Fifty iron-deficient subjects (plasma ferritin concentration < 20 µg/L; mean age ± SD: 39 
27.4 ± 9.4 years) were randomised to consume an iron-fortified breakfast cereal containing 9 mg of 40 
iron daily, with either a vitamin D3 supplement or placebo. Blood samples were collected at 41 
baseline, interim (4 weeks) and post-intervention (8 weeks) for measurement of iron and vitamin D 42 
status biomarkers. The effect of intervention was analysed using mixed-model repeated measures 43 
ANOVA. Significant increases were observed in two main haematological indices: haemoglobin 44 
concentration and haematocrit level from baseline to post-intervention in the vitamin D group, but 45 
not in the placebo group. The increase from baseline to post-intervention in haemoglobin 46 
concentration in the vitamin D group (135 ± 11 to 138 ± 10 g/L) was significantly higher compared 47 
to the placebo group (131 ± 15 to 128 ± 13 g/L) (P=0.037). The increase in haematocrit level from 48 
baseline to post-intervention was also significantly higher in the vitamin D group (42.0 ± 3.0 to 43.8 49 
± 3.4%) compared to the placebo group (41.2 ± 4.3 to 40.7 ± 3.6%) (P=0.032). Despite the non-50 
significant changes in plasma ferritin concentration, this study demonstrates that 38 µg 51 
supplemental vitamin D, consumed daily, with iron-fortified breakfast cereal led to improvement in 52 
haemoglobin concentration and haematocrit levels  in women with low iron stores. These findings 53 
may have therapeutic implications in the recovery of iron status in iron-deficient populations at a 54 
healthcare level. 55 
INTRODUCTION 56 
Combatting anaemia or iron deficiency requires a cohesive approach, as its occurrence is 57 
suggested to be multifactorial. Iron supplements have been widely used to correct iron deficiency in 58 
at-risk groups, whereas in the general population either modification of the diet or iron fortification 59 
in selected food vehicles may be implemented 
(1)
. Dietary modification requires long-term 60 
objectives, and evidence from recent experimental trials has shown that iron fortification, which is 61 
considered a medium-term strategy
(2)
, will not completely improve general iron status, whilst the 62 
efficacy of oral iron supplementation in improving iron status is often limited by low adherence as a 63 
result of adverse events following supplementation 
(3)
. The measurement of different iron 64 
parameters is fundamental to determining of iron status, due to a broad spectrum which extends 65 
between iron deficiency and iron overload, which both occur due to the failure of iron homeostasis 66 
and causes flaws at functional and structural levels 
(4)
. The presence of anaemia can be confirmed 67 
with a single biomarker of haemoglobin concentration, whilst measurement of ferritin concentration 68 
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3 
is deemed to be the best measurement to identify iron deficiency 
(5)
, on condition that there is no 69 
presence of inflammation 
(6)
. Hepcidin has been reported to be a systemic iron regulator 
(7)
 and a 70 
clearer understanding of the interaction between inflammation, erythropoiesis, and hypoxia, which 71 
are regulated by hepcidin, may benefit in designing effective iron interventions that may result in 72 
fewer adverse events
(2)
. Understanding of this interaction may require clinical laboratory-based iron 73 
interventions that are focused on measuring hepcidin and designed to be implemented in a specific 74 
population, instead of the general population
(2)
.  75 
Vitamin D, a secosteroid hormone, which exists in two major forms (D3 and D2)
(8)
 has 76 
recently been implicated in the stimulation of erythroid precursors and ultimately rate of 77 
erythropoiesis
(9)
. An in vitro study carried out in human cell lines demonstrated that administration 78 
of 25(OH)D and 1,25-dihydroxyvitamin D (1,25(OH)2D) for 6 hours led to a 50% reduction in 79 
hepcidin mRNA expression
(10)
, supporting the postulated hypothesis that hepcidin suppression may 80 
facilitate iron status regulation by increasing iron uptake and storage. Evidence from a pilot human 81 
study using 7 healthy subjects, supplemented with single oral dose of vitamin D2 (2500 µg) 82 
supports the in vitro findings, and showed that serum hepcidin concentration was significantly 83 
reduced by 34% following 24 hours (P<0.05) and by 33% after 72 hours (P<0.01) of 84 
supplementation. However, serum ferritin concentration, which signifies iron stores, was found to 85 
have significantly decreased
(10)
. A small sample size limits interpretation of the findings, however, 86 
the significant decline observed in serum hepcidin concentration, in addition to the evidence from 87 
the in vitro study
(11)
 warrants larger scale investigations.  88 
To the best of our knowledge, limited and inconsistent published evidence exists supporting 89 
the link between concurrent incidence of iron and vitamin D deficiencies in the normal population, 90 
as previous studies were predominantly carried out in kidney disease, heart failure or diabetic 91 
patients
(12)
. There is a paucity of randomised controlled trials, investigating the effect of the vitamin 92 
D supplementation administered routinely, as an iron absorption enhancer on iron status, especially 93 
in populations at risk of iron deficiency. The present study integrates the two strategies of 94 
supplementation and fortification to treat iron deficiency by using vitamin D3 supplements in 95 
combination with the consumption of iron-fortified foods, in premenopausal UK women with low 96 
iron stores. Based on existing evidence from observational, human interventions and in vitro 97 
studies, anaemia was clearly associated with the incidence of vitamin D deficiency, though no clear 98 
mechanism has been identified 
(13)
. The proposed theory, however, revolves around the mechanism 99 
of action of vitamin D that affects hepcidin expression, pro-inflammatory cytokine production, and 100 
rate of erythropoiesis 
(13; 14; 15; 16)
. We hypothesise that vitamin D supplementation will exert further 101 
improvement in haematological indices, and the measurement of plasma hepcidin concentrations, 102 
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4 
parathyroid hormone (PTH) and vitamin D binding protein (VDBP) concentrations will enable the 103 
investigation of a potential mechanism linking vitamin D and iron deficiencies.  104 
105 
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5 
SUBJECTS AND METHODS 106 
Subjects  107 
Fifty premenopausal women aged 19-49 years were recruited to the study using posters, 108 
emails, and press releases as a recruitment medium at the University of Chester and the wider city 109 
of Chester, UK. The inclusion criteria were: females, healthy, and non-pregnant nor lactating. 110 
Exclusion criteria were: history of gastrointestinal and metabolic disorders, blood donation within 111 
the past 6 months, and regular consumption of nutritional supplements. 112 
 113 
Sample size: 114 
 Sample size was estimated using serum ferritin concentrations (µg/L) from a double-blind 115 
placebo-controlled study carried out in previous study in women aged 20-40 years with serum 116 
ferritin concentrations of < 22 µg/L
(17)
. The study was designed to determine the effect of 8 weeks 117 
iron-fortified milk supplementation on iron stores. The study found no significant difference of 118 
mean (±SD) serum ferritin concentration at baseline between the iron-fortified group (13.3 ± 6.9 119 
µg/L) and control group (12.6 ± 6.8 µg/L) (P=0.69). At post-intervention, mean (±SD) serum 120 
ferritin concentrations were significantly higher (17.7 ± 11.9 µg/l) in the iron-fortified group, 121 
compared to 10.6 ± 8.1 µg/L in the control group (P=0.01). With a Cohen’s effect size (d) of 0.7, 122 
the total sample size required in the present study was 26 per group (power=0.80, α error 123 
probability = 0.05). Allowing for a 20% drop-out rate, the total sample size required was estimated 124 
to be 62 (31 subjects/group). The sample size was estimated using of G-Power Software (Version 125 
3.1.7). 126 
 127 
Recruitment and screening: 128 
A total of 186 women attended the initial screening clinics and 62 were eligible based on the 129 
plasma ferritin concentration threshold of < 20 µg/L to define marginal iron deficiency and plasma 130 
25(OH)D concentration of < 250 nmol/L. However, 12 of the eligible subjects withdrew from 131 
participating in the study. The reasons were; sickness (n=1), did not respond to the invitation email 132 
(n=6), and declined to participate following the screening session (n=5). After screening, 50 133 
subjects were included and randomised.  134 
 135 
Study design 136 
A placebo controlled, double-blind randomised controlled trial (RCT) was carried out for a period 137 
of 8 weeks. The data collection phase was between September 2015 and April 2016. The study 138 
design consisted of 2 phases: Phase 1 was the recruitment and screening phase when potential 139 
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6 
subjects were screened for iron deficiency. Phase 2 was the intervention phase where all subjects 140 
consumed iron-fortified breakfast cereal, together with either vitamin D3 supplements (vitamin D 141 
group) or placebo (placebo group) daily, for 8 weeks. This study was conducted according to the 142 
guidelines laid down in the Declaration of Helsinki and all procedures involving human subjects 143 
were approved by the Faculty of Life Sciences Research Ethics Committee (FREC reference: 144 
1078/15/SF/CSN). Written informed consent was obtained from all subjects. The present study was 145 
registered at ClinicalTrials.gov (Trial registry number: NCT02714361 - www.clinicaltrials.gov).  146 
  147 
Phase 1 (Screening): 148 
All subjects attended a screening clinic to ascertain plasma ferritin concentration, which was used to 149 
indicate physiological iron stores in the present study. During the screening clinic, 4 mL of blood 150 
was collected in a lithium heparin blood collection tube at the clinical laboratory within the 151 
Department of Clinical Sciences & Nutrition, at the University of Chester by the researcher, a 152 
trained phlebotomist. The plasma sample collected was used to determine the concentration of 153 
ferritin and 25(OH)D. Eligible subjects were then invited to continue to Phase 2 of the study. 154 
Subjects who had abnormally high plasma ferritin concentrations from the screening (n=2) were 155 
excluded from study and were advised to arrange a consultation with their general practitioner. 156 
 157 
Phase 2 (Intervention): 158 
A total of 50 subjects who were eligible to participate in the study were randomised to receive 159 
either 38 µg of vitamin D3 or placebo. Both groups were instructed to consume an iron-fortified 160 
breakfast cereals with either vitamin D3 or a placebo, daily for 8 weeks. The subjects were also 161 
provided with UHT semi-skimmed milk and were required to consume 60 g of pre-weighed iron-162 
fortified cereals provided in sealed plastic containers with 200 mL of milk in the morning every day 163 
for the duration of the study. Subjects were instructed to consume the vitamin D3 capsules or 164 
placebo capsules with 200 mL of water daily, in the evening, for the duration of the study. All 165 
subjects were reminded not to modify their dietary habits and physical activity, in addition, to 166 
abstaining from donating blood during the course of the study.  167 
 168 
Study clinics: 169 
Subjects were all required to attend clinics after overnight fasts of approximately 8 hours and were 170 
expected to attend 3 clinics in total. Subjects were asked to consume only water during the 171 
overnight fast. Each clinic lasted approximately 30 minutes and took place between 8-10 am. 172 
Details of each clinic are as follows: 173 
D
ow
nloaded from
 https://w
w
w
.cam
bridge.org/core . U
niversity of C
hester , on 26 M
ar 2019 at 16:21:22 , subject to the C
am
bridge C
ore term
s of use, available at https://w
w
w
.cam
bridge.org/core/term
s . https://doi.org/10.1017/S0007114519000412
Accepted manuscript 
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 174 
Clinic 1 (Week 0, baseline): Height (cm) was measured using a digital stadiometer and body weight 175 
(kg) measured using weighing scales, followed by collection of a 30 mL fasted venous blood 176 
sample collection. Subjects were given a 3-day food diary to be completed within the first week and 177 
returned at the next clinic. A 4-week supply of both iron-fortified breakfast cereals in individually 178 
pre-weighed sealed plastic containers and UHT semi-skimmed milk were provided to the subjects, 179 
together with a supplement bottle, containing 8 weeks of supplements with assigned subject ID. The 180 
protocol was explained to subjects and an email reminder was sent to the subjects one day before 181 
the following clinic.  182 
 183 
Clinic 2 (Week 4, interim): Body weight was measured and a 30 mL fasted venous blood was 184 
drawn. Subjects were given a further 3-day food diary to be completed during the week before the 185 
final clinic and the previous food diary was collected. A further 4-week supply of iron-fortified 186 
breakfast cereals and UHT semi-skimmed milk was provided to the subjects.  187 
 188 
Clinic 3 (Week 8, post-intervention): Body weight was measured and a 30 mL fasted venous blood 189 
was drawn. The final 3-day food diary and supplement bottle with any remaining capsules, for 190 
assessment of the compliance, were collected.   191 
 192 
Randomisation and blinding of subjects 193 
The randomisation process was carried out using computer-generated software 194 
(www.randomization.com) by a third party, independent to the study. Subjects (n=50) were 195 
randomised to 2 groups: vitamin D3 (vitamin D group) or placebo (placebo group). The third party 196 
allocated 62 capsules of vitamin D3 and placebo into each identical supplement bottle according to 197 
the generated plan. An excess of 6 capsules in each bottle enabled the researcher to estimate 198 
compliance once the study was completed. Each tamper proof bottle was then sealed and numbered, 199 
ready to be provided to subjects.  200 
The subjects and researcher were blinded to which groups subjects were assigned to. The 201 
researcher administered the numbered supplement bottle (i.e; 001) to the subjects based on the 202 
sequence that subjects attended their baseline clinic (week 0). The blinding was maintained 203 
throughout the study period of 8 weeks and allocation was not unlocked until the end of the data 204 
analysis.  205 
 206 
Iron-fortified breakfast cereals 207 
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8 
The iron-fortified breakfast cereal used in the study was a commercially available whole 208 
grain rice and wheat flakes cereal (Weight Watchers UK Ltd, Berkshire, UK). Both breakfast cereal 209 
and UHT semi-skimmed milk were provided to the subjects at Clinic 1 and 2. Subjects were 210 
instructed to consume one pre-weighed tub of cereal (60 g) containing approximately 9 mg of iron 211 
with 200 mL of UHT semi-skimmed milk (Tesco PLC, Hertfordshire, UK), daily. Each subject was 212 
also given a measuring cup to measure approximately 200 mL of UHT semi-skimmed milk to 213 
consume with the cereal, to ensure standardisation of meal consumed by each subject. It was 214 
emphasised during the first clinic that the subjects needed to consume the cereal daily. However, in 215 
the event of missing a tub of the provided cereal, it was advised that the cereal was consumed 216 
immediately, or double the amount the following day. 217 
Subjects were asked to record and report any problems regarding consumption of the 218 
provided cereal during the interim clinic (week 4) and were requested to notify researcher of any 219 
adverse events during the course of study. The specific cereal was selected as it is fortified with 220 
iron, and previous iron-fortified cereal studies have reported the use of between 7-18 mg of total 221 
iron. A total of 9 mg iron in the present study provides approximately 60% of the Reference 222 
Nutrient Intake (RNI) per day for women aged 19-50 years
(18)
. The nutritional content of the 223 
breakfast cereal as stated on the product label is shown in Table 1. 224 
 225 
Vitamin D supplement and placebo 226 
The supplement used was vitamin D3 cholecalciferol (38 µg, 1500 IU, Pharma Nord ApS, 227 
Vejle, Denmark), liquefied in cold-pressed olive oil and encapsulated in a clear soft gel 7 mm 228 
diameter capsule. Each capsule was made of a combination of olive oil, gelatine, glycerol, and 229 
purified water. The supplements were packaged in blister packs, and manufactured specific to the 230 
research requirement and according to pharmaceutical standards (EC and Scandinavia).  231 
The matching placebo was custom-produced to the requirement of the study by Pharma 232 
Nord. Placebo was identical to the gel capsule in appearance, size, colour and taste but without the 233 
active ingredients. A certificate of analysis provided by the manufacturer confirmed the vitamin D 234 
content of supplements (36.6 mcg, with limits 30.4-57 mcg).  235 
 236 
Assessment of Compliance 237 
Compliance to the supplementation (%) was estimated as follows: (62 – remaining capsules 238 
in the bottle)/56 x 100. For the total duration of 8 weeks, subjects were required to consume 56 239 
capsules of vitamin D3 or placebo.  240 
 241 
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9 
Anthropometric measurements 242 
Height (cm) and weight (kg) were measured using electronic scales (Model 875 SECA, 243 
Hamburg, Germany) and a wall mounted digital stadiometer (Model 264 SECA, Hamburg, 244 
Germany) at baseline and repeated at subsequent clinics as previously described. The instruments 245 
used were calibrated before every measurement. Body mass index (BMI) was then calculated using 246 
the equation:  BMI = weight (kg)/height (m
2
) and categorised using threshold values from the 247 
WHO.  248 
 249 
Blood handling 250 
Both whole blood and plasma obtained from the venepuncture were used for analysis. The 251 
blood sample was collected in lithium heparin and EDTA blood collection tubes (BD Company, 252 
New Jersey, USA) for blood biomarker analysis. Whole blood was used immediately after each 253 
clinic to measure full blood counts (FBC). Venous blood samples collected were centrifuged for 10 254 
minutes (1600 g) at 4
º
C to obtain plasma samples required for iron and vitamin D biomarker assays, 255 
which were then aliquoted into microcentrifuge tubes and stored at -80
 º
C before being used for 256 
analysis. Plasma samples were used to analyse iron status biomarkers (C-reactive protein, ferritin, 257 
soluble transferrin receptor (sTfR) and hepcidin) and vitamin D metabolism biomarkers (25(OH)D, 258 
PTH, and VDBP) concentrations.  259 
 260 
Measurement of iron and vitamin D biomarkers  261 
Whole blood samples were used to measure full blood counts indices using an automated 262 
Ac.T diff Haematology Analyser (Beckman Coulter, Inc., Brea, USA). The intra-assay CV for this 263 
measurement was 1.9%. 264 
Plasma samples were used for the analysis of ferritin and 25(OH)D concentrations using a 265 
miniVIDAS automated immunoanalyser (Biomerieux, Marcy-I’Etoile, France), with the detectable 266 
range of > 1.5 µg/l and 20.3 nmol/l respectively. The analytical reliability of 25(OH)D assay in 267 
miniVIDAS automated analyser used in the present study achieved the set performance target by 268 
Vitamin D External Quality Assessment Scheme (DEQAS, London, UK), with intra-assay CV of 269 
4.7% and 2.0% for ferritin and 25(OH)D, respectively. A number of plasma samples were re-270 
analysed using 25(OH)D ELISA kit (Calbiotech Inc, Spring Valley, USA) (n=32 samples from 19 271 
participants) and human ferritin ELISA kit (Elabscience Biotechnology Co. Ltd, Houston, USA) 272 
(n=3 samples from 2 participants), as the concentrations were below the detectable range of the 273 
miniVIDAS immunoanalyser. Plasma CRP, hepcidin, sTfR and VDBP concentrations were each 274 
measured using commercially available human ELISA kits specific to each biomarker (Quantikine 275 
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10 
Human Immunoassay ELISA kit, R&D Systems Inc., Minneapolis, USA) and plasma PTH 276 
concentrations were measured using commercially available human ELISA kits (Calbiotech Inc, 277 
Spring Valley, USA). The intra-assay CVs were 11.3% (25OHD), 12.9% (Ferritin), 2.7% (CRP), 278 
11.5% (Hepcidin), 5.0% (sTfR), 11.3% (VDBP) and 7.0% (PTH). 279 
Assessment of dietary intake 280 
Subjects were required to complete a 3-day food diary during the first and last weeks of the 281 
intervention (to include 2 weekdays and 1 weekend day) to estimate their habitual dietary intake. 282 
The diary comprised instructions on how to appropriately record dietary intakes, including a guide 283 
to portion sizes, how to describe the foods/drinks in detail, together with a sample diary. In each 284 
section of the diary, there were columns for time of consumption, location, description of 285 
food/drink consumed, brand and amount/quantity for the subjects to complete. Subjects were also 286 
requested to specify any physical activity performed during that particular day. If the foods/drinks 287 
consumed were homemade, there were also recipe sections provided for the subjects to specifically 288 
note in the diary. 289 
Dietary records were analysed for nutritional content using Nutritics Professional Nutrition 290 
Analysis Software (Nutritics Ltd, Dublin, Ireland). The food items used for the analysis were 291 
derived from McCance and Widdowson’s ‘The Composition of Foods’(19). The DRVs from the 292 
Committee on Medical Aspects of Food Policy (COMA) 1991
(18)
 in combination with the Scientific 293 
Advisory Committee on Nutrition (2015)
(20)
 were used as a reference to compare the intake of 294 
energy, macro, and micronutrients of the subjects. 295 
 296 
Statistical Analysis 297 
All statistical analyses were performed using IBM SPSS Statistic Data Editor Software (Version 21) 298 
(IBM Corporation, New York, USA). Shapiro-Wilks or Kolmogorov-Smirnov tests were used to 299 
determine the normal distribution of data as appropriate. Descriptive statistics were used to describe 300 
frequencies, means and standard deviations. Baseline comparisons between the groups (vitamin D 301 
and placebo groups) were carried out using independent t-test for normally distributed data or the 302 
Mann-Whitney test for non-normally distributed data. Mixed model repeated measures ANOVA 303 
was performed to determine the effect of intervention and the interaction with time points for all 304 
iron status and vitamin D status blood biomarkers. Post-hoc analyses were carried out when 305 
intervention  time point interactions were observed, to identify the differences within or between 306 
the groups. Changes in all iron status and vitamin D status blood biomarkers from baseline (week 0) 307 
to post-intervention (week 8) between the two groups were compared and analysed using 308 
independent t-test for normally distributed data or Mann-Whitney test for non-normally distributed 309 
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11 
data. Sub-group analyses (n=32) were carried out in subjects with a plasma ferritin thresholds of 310 
<15 µg/L to ascertain whether the severity of iron deficiency influenced subjects’ iron status 311 
response. Pearson’s or Spearman’s correlation coefficient tests were performed as appropriate, to 312 
investigate the associations between (i) baseline concentration of haemoglobin and 25(OH)D with 313 
changes in iron status biomarkers and vitamin D biomarkers and (ii) iron and vitamin D biomarkers. 314 
Differences and associations were considered significant with a p-value ≤ 0.05 (two-sided). 315 
RESULTS 316 
Baseline characteristics of subjects 317 
Of a total of 186 women screened, 62 were eligible and 50 women commenced the study. 318 
Four subjects dropped out after the first clinic due to feeling unwell (n=2) or without specific reason 319 
and did not respond to emails (n=2). A further two subjects dropped out after the interim clinics due 320 
to ill health therefore 44 subjects completed the intervention. The baseline characteristics are 321 
reported based on the data available for the total of 50 subjects (including drop-outs). Figure 1 322 
shows a flow diagram of study phases.  323 
The baseline characteristics of subjects are summarised in Table 2. The subjects recruited 324 
were aged between 19-49 years, with a mean (±SD) age of 27.4 ± 9.4 years. The majority of 325 
subjects were white (80%), followed by Asian (12%) and others (8%). The mean (±SD) plasma 326 
ferritin and 25(OH)D concentrations were 11.5 ± 5.6 µg/L and 38.3 ± 21.4 nmol/L, respectively. 327 
This indicates that the subjects were largely iron deficient (plasma ferritin < 15 µg/L, n=32)
(21)
 and 328 
vitamin D deficient (IOM deficient threshold of plasma 25(OH)D <30 nmol/L, n=31)
(22)
 at 329 
screening and eligible for the study. The mean (±SD) plasma 25(OH)D concentration did not 330 
change from screening to when eligible subjects commenced the study at baseline (P=0.205), which 331 
ranged between 5 and 10 days. On the contrary, a higher mean (±SD) plasma ferritin concentration 332 
was observed at baseline (13.2 ± 7.8 µg/L) compared to screening (11.5 ± 5.6 µg/L) (P=0.012). The 333 
concentrations of both plasma ferritin and 25(OH)D were not corrected for inflammation, as no 334 
subjects had elevated plasma CRP concentrations (<10 mg/L) at all time points, indicated by mean 335 
of < 4 mg/L in both groups.  336 
There were no significant differences in the subjects’ baseline physical characteristics 337 
(height, weight and BMI) between the vitamin D group and the placebo group. No significant 338 
differences in subjects’ iron and vitamin D status (haemoglobin, plasma ferritin, plasma hepcidin 339 
and plasma 25(OH)D concentrations) between the vitamin D group and the placebo group at 340 
baseline were observed. With reference to dietary intake, no significant differences in energy, 341 
protein, carbohydrate, fat, iron, vitamin D, calcium and vitamin C intake between the vitamin D 342 
group and the placebo group, except for carbohydrate (as % of energy) were detected. When 343 
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12 
excluding drop-outs (n=6) from the analysis, no significant differences in physical characteristics, 344 
iron and vitamin D status, and dietary intakes at baseline between the two groups were found.  345 
Different thresholds were used to classify anaemia (haemoglobin < 110 g/L), iron deficiency 346 
(plasma ferritin < 15 μg/L) and vitamin D deficiency (plasma 25(OH)D < 30 nmol/L). Prevalence 347 
of anaemia, iron deficiency and vitamin D deficiency at baseline were 12% (n=6), 64% (n=32) and 348 
62% (n=31) respectively. It was observed that 13% of the vitamin D deficient (VDD) participants 349 
were also anaemic and a higher proportion were iron deficient (ID) (61%). This indicates the 350 
possible association between iron status and vitamin D status, which has been shown in previous 351 
observational studies. 352 
 353 
Compliance and adverse events 354 
Overall mean (±SD) compliance of supplementation was 92.9 ± 8.0%, indicating good 355 
compliance. Compliance was similar in both groups with 93.2% in the vitamin D group compared 356 
to 92.6% in the placebo group. No subjects reported any adverse events associated with the 357 
consumption of supplements.  358 
The consumption of iron-fortified breakfast cereal was examined using the diary recorded 359 
by the subjects during the first and last weeks of the intervention. All subjects recorded 360 
consumption of the provided iron-fortified cereal at breakfast every day in both diaries indicating 361 
good compliance. There were also no adverse events reported by the subjects connected to the 362 
cereal consumption. 363 
 364 
Effect of vitamin D supplementation on iron and vitamin D status biomarkers 365 
No increase in the concentrations of the two main iron status biomarkers: haemoglobin and 366 
haematocrit level from baseline (week 0) to post-intervention (week 8) in the vitamin D group, 367 
compared to the placebo group were observed (Table 3). Figure 2 shows the improvement in 368 
haemoglobin concentration (4 g/L) in the vitamin D group was significantly higher compared to the 369 
placebo group (-3 g/L) (P=0.037). The improvement in haematocrit level was also significantly 370 
higher in the vitamin D group (1.8%) compared to the placebo group (-0.5%) (P=0.032). In the 371 
vitamin D group, consumption of vitamin D3 supplements with the iron-fortified cereals, however, 372 
did not impact upon the other iron status biomarkers including red blood cell (RBC), mean 373 
corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), mean corpuscular 374 
haemoglobin concentration (MCHC), plasma ferritin, plasma hepcidin and plasma sTfR, compared 375 
to the placebo group. 376 
 377 
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13 
Effect of vitamin D supplementation on vitamin D status biomarkers 378 
As expected, plasma 25(OH)D concentration was significantly higher in the vitamin D 379 
group, compared to the placebo group at 4-weeks and post-intervention, relative to baseline. The 380 
increase from baseline to post-intervention in plasma 25(OH)D concentration in the vitamin D 381 
group (28.0 nmol/L) was significantly higher than the change in the placebo group (-5.7 nmol/L) 382 
(P=0.0001) (Table 3). From the total number of 44 subjects who completed the study, the increase 383 
from baseline to 4-weeks in plasma 25(OH)D concentration in the vitamin D group (23.1 nmol/L) 384 
was also significantly higher than the change in the placebo group (0.2 nmol/L) (P=0.0001). In 385 
addition, the increase at post-intervention from 4-weeks in the vitamin D group (5.0 nmol/L) was 386 
also significantly higher than the change in the placebo group (-5.9 nmol/L) (P=0.003) (Mean ±SD 387 
not shown in Table 3 and Supplemental Table). However, no significant difference between the 388 
vitamin D group and the placebo group in plasma PTH and plasma VDBP concentrations were 389 
observed. 390 
 391 
Time effect of the intervention within each group on iron and vitamin D status biomarkers 392 
In the vitamin D group, mean (±SD) haemoglobin concentration was significantly higher at 393 
post-intervention (138 ± 10 g/L) compared to baseline (136 ± 12 g/L) (P=0.035) (Supplemental 394 
Table). No significant difference in haemoglobin concentration was observed within the placebo 395 
group, between each time point. In the vitamin D group, mean (±SD) haematocrit level was 396 
significantly higher at post-intervention (43.8 ± 3.4%) compared to both; baseline (42.5 ± 3.2%, 397 
P=0.017) and 4-weeks (42.7 ± 3.2%, P=0.044). No significant difference in haematocrit level was 398 
observed within the placebo group, between each time point.  399 
In the vitamin D group, mean (±SD) RBC count was significantly higher at post-400 
intervention (4.8 ± 0.3 x10
12
/L) compared to baseline (4.6 ± 0.3 x10
12
/L) (P=0.007). No difference 401 
in RBC count was observed within the placebo group, between each time point. In the vitamin D 402 
group, mean (±SD) MCHC was significantly lower at post-intervention (316 ± 10 g/L) compared to 403 
both baseline (320 ± 8 g/L, P=0.028) and 4-weeks (320 ± 8 g/L, P=0.032). No difference in MCHC 404 
was observed within the placebo group, between each time point.  405 
Difference within groups in MCH was observed in both groups. In the vitamin D group, 406 
mean (±SD) MCH was significantly lower at post-intervention (29.1 ± 1.9 pg) compared to 4-weeks 407 
(29.3 ± 1.8 pg) (P=0.017). In the placebo group, mean (±SD) MCH was significantly lower at post-408 
intervention (28.1 ± 3.0 pg) compared to both baseline (28.7 ± 3.0 pg, P=0.008) and 4-weeks (28.7 409 
± 3.0 pg, P=0.0001).  410 
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14 
No significant difference was observed within both groups in MCV, plasma ferritin, plasma 411 
hepcidin and plasma sTfR concentrations, between each time point. Based on a WHO ferritin 412 
normal threshold of >15 µg/L, there were 10 subjects in the vitamin D group who had an increase in 413 
their plasma ferritin concentrations from baseline to 4-weeks. The number of subjects who had 414 
increased plasma ferritin concentrations was slightly higher (n=13) from the 4-week time point to 415 
post-intervention, to an overall mean (±SD) plasma ferritin concentration of 16.0 ± 10.8 µg/L which 416 
is within the normal range. A similar trend was observed in the placebo group, however, the 417 
majority of the subjects in the placebo group (n=16) remained iron deficient at post-intervention, 418 
indicated by an overall mean (±SD) plasma ferritin concentration of 13.8 ± 13.3 µg/L. 419 
A sub-group analysis carried out in subjects who were iron deficient based on a plasma 420 
ferritin threshold of <15 µg/L at baseline showed no significant effect of vitamin D3 421 
supplementation on all biomarkers of iron status was observed. 422 
 423 
Association between different variables of iron and vitamin D biomarkers 424 
 Baseline haemoglobin concentrations were found to have a significant impact on the 425 
subjects’ response to iron-fortified breakfast cereal consumption (Figure 3). The more anaemic the 426 
subjects were at baseline, the greater the improvement in RBC counts, haemoglobin concentrations 427 
and haematocrit levels. Strong and moderate inverse associations between baseline haemoglobin 428 
concentration and change in RBC, haemoglobin concentration and haematocrit levels were noted. 429 
No significant association was observed between baseline plasma ferritin concentrations with any of 430 
the changes in iron status biomarkers . However, we acknowledge that if vitamin D stimulates 431 
erythropoiesis, it will draw on both endogenous reserves and stimulate dietary iron and this is 432 
indistinguishable in the present study. However, a strong and positive association was observed 433 
between plasma ferritin and plasma hepcidin concentrations (r=0.605, P=0.0001, data not shown), 434 
indicating the role of hepcidin in suppressing iron uptake once the subjects’ iron stores are replete. 435 
Positive associations were observed between baseline plasma 25(OH)D concentrations with RBC 436 
count, haemoglobin concentration and haematocrit level, as well as a significant inverse association 437 
with plasma PTH concentration, as expected (Table 4). Interestingly, improvement in plasma 438 
VDBP concentrations were found to be strongly associated with the recovery of several key full 439 
blood count indices (Table 4).   440 
 441 
Dietary iron intake following vitamin D supplementation and iron-fortified cereal consumption. 442 
 Increases in dietary iron intake were expected in both intervention groups, as both received 443 
iron-fortified cereals. However, changes in both groups were non-significant. In the vitamin D 444 
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15 
group, mean (±SD) dietary iron intake was 16.5 ± 1.8 mg/day at baseline and 16.8 ± 2.3 mg/day at 445 
post-intervention (+0.3 mg/day, P=0.6), and in the placebo group, dietary iron intake was 16.6 ± 2.7 446 
mg/day at baseline, and 17.5 ± 2.9 mg/day post-intervention (+1.0 mg/day, P=0.134). 447 
448 
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DISCUSSION  449 
 We investigated the effect of vitamin D3 supplementation with a dose of 1500 IU (38 µg), 450 
consumed with an iron-fortified breakfast cereal (9 mg) on iron status. To the best of our 451 
knowledge, this is the first RCT reporting the increase of two key haematological indices; 452 
haemoglobin concentrations and haematocrit levels following consumption of vitamin D with iron-453 
fortified foods, indicated by increased haemoglobin concentrations and haematocrit levels.  454 
Haemoglobin concentrations reflect the presence or absence of anaemia and oxygen-455 
carrying capacity required for normal cell functions, whilst haematocrit levels indicate the 456 
proportion of circulating RBCs relative to whole blood total volume. The shifts (increase or 457 
decrease) in these two key indices of iron status are typically interrelated
(23)
. The change in 458 
haemoglobin concentration (4 g/L vs -3 g/L, P=0.037) and haematocrit levels (1.8% vs -0.5%, 459 
P=0.032) were significantly higher in the vitamin D group as opposed to the placebo group. It was 460 
observed that these two biomarkers were improved in the vitamin D group, whilst diminishing in 461 
the placebo group, suggesting that daily consumption of iron-fortified cereal with vitamin D 462 
supplements, compared to only iron-fortified cereal, may exert an additional beneficial effect on 463 
iron status.  464 
Studies carried out in clinical settings among IDA and hypertensive patients 
(16; 24)
 or healthy 465 
adults 
(15)
 observed no improvement in haemoglobin, or serum ferritin concentrations. However, 466 
haemoglobin concentration and haematocrit levels were found to be significantly higher in the 467 
intervention group at 8 weeks in a iron/vitamin D fortification study by Toxqui et al. 
(25)
, but no 468 
significant impact on any iron status biomarkers was observed in a calcium/vitamin D fortification 469 
study by Hennigar et al. 
(26)
. Mean (±SD) baseline concentration of haemoglobin was 134 ± 14 g/L, 470 
and 7 of the subjects (n=50, vitamin D=3, placebo=4) were anaemic based on the WHO threshold 471 
of <120 g/L
(21)
.  472 
A greater improvement in these biomarkers may have been observed with a higher 473 
proportion of anaemic subjects at baseline, however, it was evident in the present study that the 474 
baseline concentration of haemoglobin dictates the subjects’ response to the intervention. It was 475 
previously demonstrated in a meta-analyses by Casgrain et al. 
(27)
 that participants’ response to iron 476 
intervention vastly depends on their initial iron status, and that the improvement is greater in 477 
anaemic participants, as the iron requirements are higher due to physiological demands. The mean 478 
baseline concentration of plasma 25(OH)D was also found to influence the response to intervention. 479 
Greater improvement was observed in the RBC counts, haematocrit levels, and haemoglobin 480 
concentrations, if the subjects were vitamin D deficient at baseline. Factors such as (i) 481 
amounts/form of iron and vitamin D used in the study (low/high/none or 482 
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17 
fortification/supplementation); (ii) duration of interventions; or (iii) baseline characteristic that 483 
defines anaemia or vitamin D deficiency by using different thresholds, contributes to 484 
inconsistencies in published findings.  485 
 The active metabolite of vitamin D, calcitriol has recently been demonstrated in pilot human 486 
studies to play a role in suppression of the hepcidin expression, which is dictated by a gene known 487 
as antimicrobial peptide (HAMP) 
(10; 14)
. Vitamin D has been demonstrated in previous studies to be 488 
capable of increasing proliferation of erythroid precursors in the bone marrow to support 489 
erythropoiesis by decreasing the expression of pro-inflammatory cytokines which cause the 490 
suppression of hepcidin. Decreased cytokines and suppressed hepcidin leads to higher iron 491 
bioavailability for RBC production and haemoglobin synthesis 
(14)
.  492 
The mechanism of action of vitamin D in exerting additional effects on the recovery on iron 493 
status was proposed to revolve around suppression of hepcidin expression, pro-inflammatory 494 
cytokine production, and rate of erythropoiesis. Under normal circumstances, iron homeostasis 495 
involves the circulation of transferrin-iron complexes that move to the bone marrow to produce red 496 
blood cells in erythropoiesis. The senescent erythrocytes will degenerate and will be engulfed by 497 
macrophages. Iron is then reutilised and released back into the circulation to repeat the same 498 
erythropoiesis process 
(14)
. Depending upon physiological demands, haem and non-haem dietary 499 
iron will enter the labile iron pool from intestinal iron uptake and when increased concentrations of 500 
pro-inflammatory cytokines are present, production of the RBCs in the bone marrow is suppressed. 501 
This will then lower half-life of RBCs as a result of elevated macrophages and phagocytic activity 502 
activation. IL-6 and IL-1β are among the cytokines that are capable of stimulating the liver into 503 
increasing production of the HAMP gene, which leads to increased or decreased iron uptake 
(14)
. 504 
Observational studies in different populations previously reported the concurrent incidence 505 
of both vitamin D deficiency and anaemia
(12; 28)
. Whilst it is evident that hepcidin is the principal 506 
iron regulator, the underpinning mechanism of the action of vitamin D on iron status is unclear as 507 
there is very limited evidence in humans, and is largely from in vitro and in vivo studies.  508 
We hypothesise that the action of vitamin D on the recovery of iron status occurs via a 509 
mechanism by which vitamin D suppresses plasma hepcidin expression, leading to an increase in 510 
ferroportin availability for iron uptake, and ultimately increases plasma ferritin concentration in 511 
subjects with low iron stores. A recent in vivo study observed that a single bolus oral ingestion of 512 
2500 µg vitamin D2 led to a significant decrease in serum hepcidin concentrations at 24 hours (34%, 513 
P<0.05) and 72 hours (33%, P<0.01)
(10)
. Vitamin D also potently decreased transcription of the 514 
HAMP gene that regulates hepcidin expression, however, no significant improvement in iron stores 515 
was observed following supplementation, which is likely due to the inclusion of healthy iron replete 516 
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18 
subjects at baseline in the study. A further in vitro study reported at least a 15-fold suppression of 517 
the HAMP gene in a monocyte cell line (THP-1) after 6 hours of treatment with 1,25(OH)2D
(11)
, 518 
indicating the direct action of vitamin D on HAMP gene transcription. The in vivo part of the study 519 
in which 38 kidney patients were supplemented with vitamin D3 (1250 µg) found a moderate, 520 
significant, negative association between the serum hepcidin and serum 25(OH)D concentrations 521 
(r=-0.38, P=0.02)
(11)
.  522 
The findings from the present study showed that vitamin D supplementation led to 523 
improvement in  two key indices of iron status: haemoglobin and haematocrit, and are consistent 524 
with limited published evidence
(25)
.  525 
Hepcidin expression was suppressed in a vitamin D supplementation study (carried out 526 
without any iron intervention)
(14)
 and in an earlier study
(10)
 in an attempt to investigate the 527 
underlying mechanism behind the action of vitamin D on iron regulation. Both studies did not 528 
observe a significant effect of the vitamin D intervention on the improvement of iron stores, 529 
indicated by plasma ferritin concentrations, which is consistent with the present study. On the 530 
contrary, the present study did not observe any significant influence of vitamin D intervention on 531 
hepcidin expression, as reported in previous studies
(10; 14)
. However, 5 subjects had increased 532 
haemoglobin concentrations, haematocrit levels and simultaneously decreased hepcidin 533 
concentrations. In this group of subjects, mean (±SD) haemoglobin concentration and haematocrit 534 
level were significantly higher at post-intervention (137 ± 15 g/L; 44.1 ± 5.0%) compared to 535 
baseline (127 ± 13 g/L; 39.5 ± 3.2%) (P=0.042; 0.043), simultaneously with significant reduction in 536 
hepcidin concentration from 8.1 ± 8.0 ng/mL at baseline to 3.1 ± 3.3 ng/mL at post-intervention 537 
(P=0.043). However, 5 subjects who had increases in both haemoglobin concentrations and 538 
haematocrit levels did not show a reduction in hepcidin concentrations.  539 
The present study observed a strong association between plasma hepcidin and plasma 540 
ferritin concentrations, however, both biomarkers were not affected by vitamin D supplementation.  541 
The vitamin D3 dose used in the present study may have been a limitation and was not sufficient to 542 
have substantially affected hepcidin expression, thus, no improvement was observed in the recovery 543 
of iron stores, indicated by plasma ferritin concentrations. Also, the vitamin D used in the present 544 
study may have not been sufficient to act on both biomarkers in a relatively short study duration of 545 
8-weeks, to allow for a substantial effect to be observed.  546 
An intriguing finding in the present study was the strong link between VDBP concentration 547 
and iron status improvement, which has not been identified previously. Improvement in plasma 548 
VDBP concentrations were strongly associated with the recovery of the RBC counts (r=0.653, 549 
P=0.002), MCV (r=0.612, P=0.004), haematocrit levels (r=0.751, P=0.0001), haemoglobin 550 
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19 
(r=0.638, P=0.002) and MCH concentrations (r=-0.592, P=0.006). On the basis of this observation, 551 
further substantial restoration may be observed in other iron status biomarkers, especially plasma 552 
hepcidin and plasma ferritin concentrations, if a higher dose of vitamin D is used.  Similar studies 553 
by Bacchetta et al.
(10)
 and Smith et al. 
(14)
 used much higher doses of vitamin D in single boluses of 554 
2500 ug vitamin D2 and 6250 ug vitamin D3, respectively. VDBP is known for its role as a 555 
25(OH)D transporter, and , and Dastani et al.
(29)
 previously previously demonstrated an association 556 
between 25(OH)D and VDBP. This observation is sufficient to connect the action of vitamin D with 557 
improvement of iron status, and warrants further investigation. 558 
The subjects’ energy, macronutrients, iron, and vitamin D intake were unchanged from 559 
baseline to post-intervention. Interestingly, mean daily iron intake of subjects, in particular, was 560 
1.7-fold higher at baseline, relative to typical iron intake of adult women reported in the UK 561 
NDNS
(30)
. This increased intake remained higher at post-intervention. This may be due to the fact 562 
that participants may have increased their intake of iron-containing foods after being informed of 563 
their iron-deficient status following screening but before they commenced the study. Despite 564 
reduction in the placebo group, the present study also demonstrated the effectiveness of iron-565 
fortified breakfast cereal (irrespective of vitamin D intervention) on raising principal iron 566 
biomarkers which is in agreement with recent findings
(31; 32; 33; 34)
.  567 
 The present study shows that concurrent incidence of both vitamin D and iron deficiency 568 
exists in women with low iron stores, and the clinical aspects of the findings may potentially be 569 
applied to the recovery of iron status in iron deficient population at a healthcare level through the 570 
therapeutic use of vitamin D supplementation as a novel iron absorption enhancer. Iron-fortified 571 
breakfast cereals were found to be efficient as a food fortification vehicle, which could be a suitable 572 
adjunct in management of iron deficiency. One limitation of the study was the failure to attain 573 
required sample size, with a shortfall of 8 participants due to 12 eligible subjects who decided not to 574 
partake in the study following screening.  A major strength of present study is the double-blind 575 
randomised controlled trial study design, carried out in a specific population of marginally low and 576 
low iron stores, which allows interpretation of findings to be extrapolated in clinical settings and 577 
included specific measurement of vitamin D biomarkers which was not measured in previous 578 
studies.  579 
In conclusion, vitamin D, consumed daily in supplement form, at a dose of 38 µg (1500 IU), 580 
was shown to lead to the recovery of haemoglobin concentrations and haematocrit levels in female 581 
subjects with marginal and low iron stores. The finding in the present study that shows baseline 582 
concentration of haemoglobin plays a role in dictating subjects’ response to intervention adds to and 583 
strengthens the existing published literature. The study also demonstrated concurrent incidence of 584 
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20 
both iron and vitamin D deficiencies in subjects, supporting the findings from observational studies 585 
carried out in various settings, and was the basis of the postulated hypothesis related to vitamin D 586 
mechanism of action on iron status regulation. A strong link between VDBP upregulation and iron 587 
status improvement, which has not been recognised previously, was also identified and merits 588 
further investigation. 589 
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Figure legends 686 
Figure 1. Flow diagram of the screening and intervention phase. 687 
 688 
Figure 2. Effect of intervention on mean (±SD) haemoglobin concentration and haematocrit level 689 
from baseline (week 0) to post-intervention (week 8). Error bars represent SD. Mean change in 690 
haemoglobin concentration (+4 g/dL) and haematocrit level (+1.8%) are significantly higher in the 691 
vitamin D group compared to placebo group. *Represents significant difference from placebo group 692 
(P <0.05). 693 
 694 
Figure 3. Association between baseline haemoglobin concentrations, and change from baseline 695 
(week 0) to post-intervention (week 8) in (a) RBC count (b) haemoglobin concentration (c) 696 
haematocrit level (n=44)697 
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Table 1. Nutritional composition of iron-fortified breakfast cereal 698 
Nutrient Per 100 g Per recommended serving (60 g) 
Energy (kJ/kcal)  1566/370 940/222 
Fat (g) 2.1 1.2 
     Saturated  0.4 0.2 
Carbohydrates (g) 70 42 
     Sugars 16 9.6 
Fibre (g) 7.5 4.6 
Protein (g) 14 8.4 
Sodium (mg) 240 160 mg 
Iron (mg) 15.0 9 
*Nutritional composition information sourced from the product label 699 
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Table 2. Baseline physical characteristics, iron and vitamin D status and dietary intake of subjects (n=50) 
 
Variables All (n=50) Vitamin D group (n=25) Placebo group (n=25) P-value  
 Mean SD Mean SD Mean SD  
Physical characteristics        
Age (years) 27.4 9.4 28.0 9.0 26.9 9.9 0.280 
BMI (kg/m
2
) 24.4  4.8 24.9 5.7 24.0 3.7 0.930 
Iron & vitamin D status  
Haemoglobin (g/L) 134 14 136  12 132 15 0.210 
Plasma ferritin (µg/L) 13.2 7.8 14.1  7.7 12.4 8.0 0.467 
Plasma hepcidin (x10
3
ng/L)  3.5 4.3 4.2 5.7 2.9 2.2 0.968 
Plasma 25(OH)D (nmol/L) 36.8   23.6 35.0 19.8 38.6 27.2 0.992 
Mean daily dietary intake 
Energy (MJ) 6.9  1.6 7.2 1.3 6.8 1.8 0.404 
Protein (g) 70.0  16.4 74.7 16.4 66.1 15.6 0.155 
Carbohydrate (%) 51.8  6.3 49.5 6.3 53.6 5.7 *0.025 
Fats (%) 30.6  7.0 31.1 6.8 30.1 7.2 0.626 
Iron (mg) 16.4   2.3 16.5 1.8 16.4 2.6 0.108 
Vitamin D (µg) 1.7   1.6 1.4 1.0 1.8 2.0 0.813 
Calcium (mg) 813.3  246.8 817.8 170.1 858.4 300.8 0.816 
Vitamin C (mg) 83.5  43.6 81.7 42.6 85.1 39.9 0.482 
P-values in bold represent a significant difference between the vitamin D and the placebo group at baseline. Independent t-test or the Mann-Whitney 
test was used depending on normal distribution of data. 
https://doi.org/10.1017/S0007114519000412
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Table 3. Effect of intervention on iron and vitamin D status biomarkers from baseline to post-intervention (n=44) 
 
Biomarkers Vitamin D group Placebo group P-value 
 Baseline Post -intervention Change Baseline Post-intervention Change  
 Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD  
Hb (g/L) 135 11 138  10 4  7 131 15 128  13 -3  12 *0.037 
Hct (%) 42.0 3.0 43.8 3.4 1.8  3.1 41.2  4.3 40.7 3.6 -0.5  3.7 *0.032 
RBC (x10
12
/L) 4.6 0.3 4.8  0.3 0.2 0.2 4.6  0.4 4.6  0.3 -0.0 0.4 0.055 
MCV (fL) 91.3  5.1 91.9  5.7 0.7  3.3 89.7  7.4 89.0  7.8 -0.6  3.1 0.117 
MCH (pg) 29.3  2.0 29.1  1.9 -0.2 0.6 28.6  3.0 28.1  3.0 -0.4  0.7 0.328 
MCHC (g/L) 321 7 316  10 -5 10 318  11 315  11 -3  9 0.425 
Fer (µg/L) 14.1 8.2 16.0   10.8 1.9  11.1 12.3 8.1 13.8   13.3 1.5  9.1 0.540 
Hep (x10
3
ng/L) 3.7 4.9 4.1  4.1 0.5 5.8 2.9  2.2 3.4  5.6 0.6  4.5 0.451 
sTfR (mg/L) 1.6 0.7 1.8   1.0 0.2  0.3 1.9  1.2 2.0  1.4 0.1  0.3 0.724 
CRP (mg/L) 2.1 2.1 2.8 3.2 0.6 2.9 3.1 3.3 3.2 3.8 0.1 4.1 0.642 
25(OH)D (nmol/L) 35.2   18.4 62.2  16.1 28.0 28.0 39.3  27.6 34.2  23.6 -5.7 9.7 *0.0001 
PTH (pmol/L) 8.3  8.9 7.2  7.8 -1.1 2.0 7.8   4.4 7.6 3.7 -0.2 2.6 0.198 
VDBP (x10
3
µg/L) 294.9  131.2 289.1 118.7 -5.89  52.2 374.0  144.0 382.7 138.1 8.6  62.2 0.413 
Hb, haemoglobin; Hct, haematocrit; RBC, red blood cells; MCV, mean corpuscular volume; MCH, mean corpuscular haemoglobin; MCHC, mean 
corpuscular haemoglobin concentration; Fer, ferritin; Hep, hepcidin; sTfR, soluble transferrin receptor; 25(OH)D, 25-hydroxy vitamin D; PTH, 
parathyroid hormone; VDBP, vitamin D binding protein. 
https://doi.org/10.1017/S0007114519000412
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P-values in bold represent a significant difference in changes from baseline (week 0) to post-intervention (week 8) observed between the vitamin D 
and placebo groups. Independent t-test or the Mann-Whitney test was used depending on normal distribution of data.  
https://doi.org/10.1017/S0007114519000412
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Table 4. Association between iron and vitamin D biomarkers (n=44) 
 
 Baseline 25(OH)D (nmol/L) VDBP (µg/mL) 
 r p r p 
RBC (x10
12
/L) 0.339 0.0001 0.653 0.002 
Hb (g/L) 0.208 0.014 0.638 0.002 
Hct (%) 0.199 0.018 0.751 0.0001 
PTH (pmol/L) -0.229 0.006 - 
MCV (fL) - 0.612 0.004 
MCH (pg) - -0.592 0.006 
Hb, haemoglobin; Hct, haematocrit; RBC, red blood cells; MCV, mean corpuscular volume; MCH, 
mean corpuscular haemoglobin; 25(OH)D, 25-hydroxy vitamin D; PTH, parathyroid hormone; 
VDBP, vitamin D binding protein. 
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Figure 1. Flow diagram of subjects in the screening and intervention phase 
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Figure 2. Effect of intervention on mean (±SD) haemoglobin concentration and haematocrit 
level from baseline (week 0) to post-intervention (week 8). Error bars represent SD. Mean 
change in haemoglobin concentration (+4 g/L) and haematocrit level (+1.8%) are 
significantly higher in the vitamin D group compared to placebo group. *Represents 
significant difference from placebo group. 
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Figure 3. Association between baseline haemoglobin concentrations, and change from 
baseline (week 0) to post-intervention (week 8) in (a) RBC count (b) haemoglobin 
concentration (c) haematocrit level (n=44) 
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